Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.
Identifieur interne : 002099 ( PubMed/Corpus ); précédent : 002098; suivant : 002100Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.
Auteurs : Caroline A. Sabin ; Peter Reiss ; Lene Ryom ; Andrew N. Phillips ; Rainer Weber ; Matthew Law ; Eric Fontas ; Amanda Mocroft ; Stephane De Wit ; Colette Smith ; Francois Dabis ; Antonella D'Arminio Monforte ; Wafaa El-Sadr ; Jens D. LundgrenSource :
- BMC medicine [ 1741-7015 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (therapeutic use), Australia, Dideoxynucleosides (therapeutic use), Europe, Female, HIV Infections (drug therapy), HIV Infections (epidemiology), Humans, Logistic Models, Male, Medication Therapy Management (statistics & numerical data), Medication Therapy Management (trends), Middle Aged, Myocardial Infarction (epidemiology), Odds Ratio, Pharmacovigilance, Practice Patterns, Physicians' (trends), Risk Assessment (methods), Risk Factors, United States.
- MESH :
- chemical , therapeutic use : Anti-HIV Agents, Dideoxynucleosides.
- drug therapy : HIV Infections.
- epidemiology : HIV Infections, Myocardial Infarction.
- methods : Risk Assessment.
- statistics & numerical data : Medication Therapy Management.
- trends : Medication Therapy Management, Practice Patterns, Physicians'.
- Adult, Australia, Europe, Female, Humans, Logistic Models, Male, Middle Aged, Odds Ratio, Pharmacovigilance, Risk Factors, United States.
Abstract
In March 2008, the D:A:D study published results demonstrating an increased risk of myocardial infarction (MI) for patients on abacavir (ABC). We describe changes to the use of ABC since this date, and investigate changes to the association between ABC and MI with subsequent follow-up.
DOI: 10.1186/s12916-016-0588-4
PubMed: 27036962
Links to Exploration step
pubmed:27036962Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.</title><author><name sortKey="Sabin, Caroline A" sort="Sabin, Caroline A" uniqKey="Sabin C" first="Caroline A" last="Sabin">Caroline A. Sabin</name><affiliation><nlm:affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK. c.sabin@ucl.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Reiss, Peter" sort="Reiss, Peter" uniqKey="Reiss P" first="Peter" last="Reiss">Peter Reiss</name><affiliation><nlm:affiliation>Academic Medical Center, Division of Infectious Diseases and Department of Global Health, University of Amsterdam, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Ryom, Lene" sort="Ryom, Lene" uniqKey="Ryom L" first="Lene" last="Ryom">Lene Ryom</name><affiliation><nlm:affiliation>Denmark Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Phillips, Andrew N" sort="Phillips, Andrew N" uniqKey="Phillips A" first="Andrew N" last="Phillips">Andrew N. Phillips</name><affiliation><nlm:affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Weber, Rainer" sort="Weber, Rainer" uniqKey="Weber R" first="Rainer" last="Weber">Rainer Weber</name><affiliation><nlm:affiliation>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Law, Matthew" sort="Law, Matthew" uniqKey="Law M" first="Matthew" last="Law">Matthew Law</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales (UNSW), Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Fontas, Eric" sort="Fontas, Eric" uniqKey="Fontas E" first="Eric" last="Fontas">Eric Fontas</name><affiliation><nlm:affiliation>Department of Public Health, Nice University Hospital, Nice, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mocroft, Amanda" sort="Mocroft, Amanda" uniqKey="Mocroft A" first="Amanda" last="Mocroft">Amanda Mocroft</name><affiliation><nlm:affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="De Wit, Stephane" sort="De Wit, Stephane" uniqKey="De Wit S" first="Stephane" last="De Wit">Stephane De Wit</name><affiliation><nlm:affiliation>Le Centre Hospitalier Universitaire (CHU) Saint-Pierre, Department of Infectious Diseases, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Colette" sort="Smith, Colette" uniqKey="Smith C" first="Colette" last="Smith">Colette Smith</name><affiliation><nlm:affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Dabis, Francois" sort="Dabis, Francois" uniqKey="Dabis F" first="Francois" last="Dabis">Francois Dabis</name><affiliation><nlm:affiliation>Université Bordeaux Segalen, INSERM U897, Epidemiologie-Biostatistique, CHU de Bordeaux, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="D Arminio Monforte, Antonella" sort="D Arminio Monforte, Antonella" uniqKey="D Arminio Monforte A" first="Antonella" last="D'Arminio Monforte">Antonella D'Arminio Monforte</name><affiliation><nlm:affiliation>Dipartimento di Scienze della Salute, Clinica di Malattie Infectitive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="El Sadr, Wafaa" sort="El Sadr, Wafaa" uniqKey="El Sadr W" first="Wafaa" last="El-Sadr">Wafaa El-Sadr</name><affiliation><nlm:affiliation>ICAP-Columbia University and Harlem Hospital, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lundgren, Jens D" sort="Lundgren, Jens D" uniqKey="Lundgren J" first="Jens D" last="Lundgren">Jens D. Lundgren</name><affiliation><nlm:affiliation>Denmark Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27036962</idno><idno type="pmid">27036962</idno><idno type="doi">10.1186/s12916-016-0588-4</idno><idno type="wicri:Area/PubMed/Corpus">002099</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002099</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.</title><author><name sortKey="Sabin, Caroline A" sort="Sabin, Caroline A" uniqKey="Sabin C" first="Caroline A" last="Sabin">Caroline A. Sabin</name><affiliation><nlm:affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK. c.sabin@ucl.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Reiss, Peter" sort="Reiss, Peter" uniqKey="Reiss P" first="Peter" last="Reiss">Peter Reiss</name><affiliation><nlm:affiliation>Academic Medical Center, Division of Infectious Diseases and Department of Global Health, University of Amsterdam, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Ryom, Lene" sort="Ryom, Lene" uniqKey="Ryom L" first="Lene" last="Ryom">Lene Ryom</name><affiliation><nlm:affiliation>Denmark Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Phillips, Andrew N" sort="Phillips, Andrew N" uniqKey="Phillips A" first="Andrew N" last="Phillips">Andrew N. Phillips</name><affiliation><nlm:affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Weber, Rainer" sort="Weber, Rainer" uniqKey="Weber R" first="Rainer" last="Weber">Rainer Weber</name><affiliation><nlm:affiliation>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Law, Matthew" sort="Law, Matthew" uniqKey="Law M" first="Matthew" last="Law">Matthew Law</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales (UNSW), Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Fontas, Eric" sort="Fontas, Eric" uniqKey="Fontas E" first="Eric" last="Fontas">Eric Fontas</name><affiliation><nlm:affiliation>Department of Public Health, Nice University Hospital, Nice, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mocroft, Amanda" sort="Mocroft, Amanda" uniqKey="Mocroft A" first="Amanda" last="Mocroft">Amanda Mocroft</name><affiliation><nlm:affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="De Wit, Stephane" sort="De Wit, Stephane" uniqKey="De Wit S" first="Stephane" last="De Wit">Stephane De Wit</name><affiliation><nlm:affiliation>Le Centre Hospitalier Universitaire (CHU) Saint-Pierre, Department of Infectious Diseases, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Colette" sort="Smith, Colette" uniqKey="Smith C" first="Colette" last="Smith">Colette Smith</name><affiliation><nlm:affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Dabis, Francois" sort="Dabis, Francois" uniqKey="Dabis F" first="Francois" last="Dabis">Francois Dabis</name><affiliation><nlm:affiliation>Université Bordeaux Segalen, INSERM U897, Epidemiologie-Biostatistique, CHU de Bordeaux, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="D Arminio Monforte, Antonella" sort="D Arminio Monforte, Antonella" uniqKey="D Arminio Monforte A" first="Antonella" last="D'Arminio Monforte">Antonella D'Arminio Monforte</name><affiliation><nlm:affiliation>Dipartimento di Scienze della Salute, Clinica di Malattie Infectitive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="El Sadr, Wafaa" sort="El Sadr, Wafaa" uniqKey="El Sadr W" first="Wafaa" last="El-Sadr">Wafaa El-Sadr</name><affiliation><nlm:affiliation>ICAP-Columbia University and Harlem Hospital, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lundgren, Jens D" sort="Lundgren, Jens D" uniqKey="Lundgren J" first="Jens D" last="Lundgren">Jens D. Lundgren</name><affiliation><nlm:affiliation>Denmark Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</nlm:affiliation></affiliation></author></analytic><series><title level="j">BMC medicine</title><idno type="eISSN">1741-7015</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (therapeutic use)</term><term>Australia</term><term>Dideoxynucleosides (therapeutic use)</term><term>Europe</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Medication Therapy Management (statistics & numerical data)</term><term>Medication Therapy Management (trends)</term><term>Middle Aged</term><term>Myocardial Infarction (epidemiology)</term><term>Odds Ratio</term><term>Pharmacovigilance</term><term>Practice Patterns, Physicians' (trends)</term><term>Risk Assessment (methods)</term><term>Risk Factors</term><term>United States</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Dideoxynucleosides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Infections</term><term>Myocardial Infarction</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Risk Assessment</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Medication Therapy Management</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Medication Therapy Management</term><term>Practice Patterns, Physicians'</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Australia</term><term>Europe</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Pharmacovigilance</term><term>Risk Factors</term><term>United States</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In March 2008, the D:A:D study published results demonstrating an increased risk of myocardial infarction (MI) for patients on abacavir (ABC). We describe changes to the use of ABC since this date, and investigate changes to the association between ABC and MI with subsequent follow-up.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27036962</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>02</Day></DateCreated><DateCompleted><Year>2016</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2016</Year><Month>Mar</Month><Day>31</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.</ArticleTitle><Pagination><MedlinePgn>61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-016-0588-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In March 2008, the D:A:D study published results demonstrating an increased risk of myocardial infarction (MI) for patients on abacavir (ABC). We describe changes to the use of ABC since this date, and investigate changes to the association between ABC and MI with subsequent follow-up.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 49,717 D:A:D participants were followed from study entry until the first of an MI, death, 1 February 2013 or 6 months after last visit. Associations between a person's 10-year cardiovascular disease (CVD) risk and the likelihood of initiating or discontinuing ABC were assessed using multivariable logistic/Poisson regression. Poisson regression was used to assess the association between current ABC use and MI risk, adjusting for potential confounders, and a test of interaction was performed to assess whether the association had changed in the post-March 2008 period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Use of ABC increased from 10 % of the cohort in 2000 to 20 % in 2008, before stabilising at 18-19 %. Increases in use pre-March 2008, and subsequent decreases, were greatest in those at moderate and high CVD risk. Post-March 2008, those on ABC at moderate/high CVD risk were more likely to discontinue ABC than those at low/unknown CVD risk, regardless of viral load (≤1,000 copies/ml: relative rate 1.49 [95 % confidence interval 1.34-1.65]; >1,000 copies/ml: 1.23 [1.02-1.48]); no such associations were seen pre-March 2008. There was some evidence that antiretroviral therapy (ART)-naïve persons at moderate/high CVD risk post-March 2008 were less likely to initiate ABC than those at low/unknown CVD risk (odds ratio 0.74 [0.48-1.13]). By 1 February 2013, 941 MI events had occurred in 367,559 person-years. Current ABC use was associated with a 98 % increase in MI rate (RR 1.98 [1.72-2.29]) with no difference in the pre- (1.97 [1.68-2.33]) or post- (1.97 [1.43-2.72]) March 2008 periods (interaction P = 0.74).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite a reduction in the channelling of ABC for patients at higher CVD risk since 2008, we continue to observe an association between ABC use and MI risk. Whilst confounding cannot be fully ruled out, this further diminishes channelling bias as an explanation for our findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabin</LastName><ForeName>Caroline A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK. c.sabin@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiss</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Academic Medical Center, Division of Infectious Diseases and Department of Global Health, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryom</LastName><ForeName>Lene</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Denmark Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales (UNSW), Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontas</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Public Health, Nice University Hospital, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mocroft</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Le Centre Hospitalier Universitaire (CHU) Saint-Pierre, Department of Infectious Diseases, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Colette</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Research Department of Infection and Population Health, University College London (UCL), Royal Free Campus, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabis</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Université Bordeaux Segalen, INSERM U897, Epidemiologie-Biostatistique, CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>d'Arminio Monforte</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze della Salute, Clinica di Malattie Infectitive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Sadr</LastName><ForeName>Wafaa</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>ICAP-Columbia University and Harlem Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundgren</LastName><ForeName>Jens D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Denmark Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>D:A:D Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AI042170</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI046362</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI069907</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015224">Dideoxynucleosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>WR2TIP26VS</RegistryNumber><NameOfSubstance UI="C106538">abacavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):413-9</RefSource><PMID Version="1">26536316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2015 Aug 1;61(3):445-52</RefSource><PMID Version="1">25908684</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 1994 Jul;90(1):583-612</RefSource><PMID Version="1">8026046</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Apr 26;356(17):1723-35</RefSource><PMID Version="1">17460226</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2008 Apr 26;371(9622):1417-26</RefSource><PMID Version="1">18387667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Sep 12;22(14):F17-24</RefSource><PMID Version="1">18753925</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Nov 30;22(18):2540-3</RefSource><PMID Version="1">19005279</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2009 May 1;51(1):20-8</RefSource><PMID Version="1">19282778</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Sep 24;23(15):2021-7</RefSource><PMID Version="1">19542863</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2009 Nov 15;49(10):1591-601</RefSource><PMID Version="1">19842973</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2010 Feb;11(2):130-6</RefSource><PMID Version="1">19682101</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Jan 28;24(3):F1-9</RefSource><PMID Version="1">20009917</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Jun 19;24(10):1509-17</RefSource><PMID Version="1">20505494</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Jun 1;24(9):1259-66</RefSource><PMID Version="1">20453628</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 2010 Jul 26;170(14):1228-38</RefSource><PMID Version="1">20660842</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501</RefSource><PMID Version="1">20543702</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Nov 13;24(17):2657-63</RefSource><PMID Version="1">20827168</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2011 Apr 1;52(7):929-40</RefSource><PMID Version="1">21427402</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2011 Jul 1;53(1):84-91</RefSource><PMID Version="1">21653308</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Jun 19;25(10):1289-98</RefSource><PMID Version="1">21516027</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):245-53</RefSource><PMID Version="1">21499115</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2011 Oct 15;204(8):1202-10</RefSource><PMID Version="1">21917893</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):615-9</RefSource><PMID Version="1">20827215</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Oct 23;25(16):1993-2004</RefSource><PMID Version="1">21716077</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Infect Dis. 2011;11:267</RefSource><PMID Version="1">21970555</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Nov 28;25(18):2243-8</RefSource><PMID Version="1">21941165</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2012 Feb 15;175(4):250-62</RefSource><PMID Version="1">22223710</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):247-58</RefSource><PMID Version="1">22507337</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2012;17(4):755-61</RefSource><PMID Version="1">22301072</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):e98-101</RefSource><PMID Version="1">22728753</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2012 Jul 17;26(11):1371-85</RefSource><PMID Version="1">22546988</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):359-68</RefSource><PMID Version="1">22592585</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):441-7</RefSource><PMID Version="1">22932321</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2012 Dec;28(12):1561-4</RefSource><PMID Version="1">22463776</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2012;17(8):1615-9</RefSource><PMID Version="1">22954798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2013 Jan 28;27(3):381-9</RefSource><PMID Version="1">23079800</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(3):e59551</RefSource><PMID Version="1">23555704</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thromb Haemost. 2013 Aug;110(2):349-57</RefSource><PMID Version="1">23703656</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2013 Nov 1;208(9):1448-53</RefSource><PMID Version="1">23908487</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2014 Jan;15 Suppl 1:1-85</RefSource><PMID Version="1">24330011</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2013 Nov 13;27(17):2749-58</RefSource><PMID Version="1">23842126</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):167-74</RefSource><PMID Version="1">24121755</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2014;19(2):141-7</RefSource><PMID Version="1">23985706</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Epidemiology. 2014 May;25(3):406-17</RefSource><PMID Version="1">24713880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int Assoc Provid AIDS Care. 2014 Mar-Apr;13(2):153-9</RefSource><PMID Version="1">23887923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lipids Health Dis. 2014;13:90</RefSource><PMID Version="1">24884881</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rev Cardiovasc Med. 2014;15 Suppl 1:S21-9</RefSource><PMID Version="1">24987860</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):413-21</RefSource><PMID Version="1">25932884</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2003 Apr;4(2):79-86</RefSource><PMID Version="1">12702127</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015224" MajorTopicYN="N">Dideoxynucleosides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054539" MajorTopicYN="N">Medication Therapy Management</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="N">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4815070</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abacavir</Keyword><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Channelling bias</Keyword><Keyword MajorTopicYN="N">Confounding</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27036962</ArticleId><ArticleId IdType="doi">10.1186/s12916-016-0588-4</ArticleId><ArticleId IdType="pii">10.1186/s12916-016-0588-4</ArticleId><ArticleId IdType="pmc">PMC4815070</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002099 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002099 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27036962
|texte= Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27036962" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |